Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma

NCT02236546 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT02236546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02236546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Not applicable
Overall status
Terminated
Start date
May 31, 2012
Completion date
November 30, 2015
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent melanoma, stage iiia melanoma, stage iiib melanoma, stage iiic melanoma, stage iv melanoma